BioSpace News Archive

As hospitals look for new and innovative ways to battle deadly pathogens and kill multi-drug resistant organisms that can cause health care-associated infections, Aultman Hospital has taken a leap into the future with six LightStrike Germ-Zapping Robots that destroy hard-to-kill superbugs in hard-to-clean places.

AdMeTech Foundation’s 11th Annual Prostate Cancer Awareness Day at the State House Highlights Massachusetts Model of National Leadership in Public Awareness, Education and Research

Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) (“Cryoport” or “the Company”), the world’s leading temperature-controlled logistics company dedicated to the life sciences industry, today announced that the Company will report financial results for the first quarter ended March 31, 2019 on Thursday, May 2, 2019 after U.S. markets close.

Triple-S Management Corporation (NYSE: GTS) today announced that it plans to release financial results for the first quarter ended March 31, 2019 before the market opens on Thursday, May 9, 2019.

Roche presented data demonstrating the use of GCP-compliant quantitative MRM mass spectrometry platform in clinical trials

Independent reviewer authorizes coverage of ReWalk system for another paralyzed individual, the 17th by a regional BCBS plan

NaBITA pioneered this tool in 2009, and since its introduction, the NaBITA Threat Assessment Tool has become the most widely used risk rubric by behavioral intervention teams in the United States.

CANbridge Pharmaceuticals Inc. announced that it has appointed Glenn Hassan to the position of Chief Financial Officer and Chief Business Officer, and Gerald F. Cox, MD, PhD, as Chief Development Strategist and interim Chief Medical Officer, effective as of April.

The Ohio Mesothelioma Victims Center says, “We are urging a Navy Veteran, factory worker or a skilled trades worker with recently confirmed mesothelioma or asbestos exposure lung cancer in Ohio to call us anytime at 800-714-0303 for direct access to famed attorney Erik Karst founding partner of the law firm of Karst von Oiste.

New vial options deliver on CSL Behring’s heritage of innovation by providing more alternatives to patients